- Home
- GNPX vs GTBP Comparison
GNPX vs GTBP Comparison
Compare GNPX & GTBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNPX
- GTBP
- Stock Information
- Founded
- GNPX 2009
- GTBP 1965
- Country
- GNPX United States
- GTBP United States
- Employees
- GNPX N/A
- GTBP N/A
- Industry
- GNPX Biotechnology: Pharmaceutical Preparations
- GTBP Biotechnology: Pharmaceutical Preparations
- Sector
- GNPX Health Care
- GTBP Health Care
- Exchange
- GNPX Nasdaq
- GTBP Nasdaq
- Market Cap
- GNPX 5.5M
- GTBP 5.5M
- IPO Year
- GNPX 2018
- GTBP N/A
- Fundamental
- Price
- GNPX $0.25
- GTBP $0.80
- Analyst Decision
- GNPX
- GTBP Strong Buy
- Analyst Count
- GNPX 0
- GTBP 1
- Target Price
- GNPX N/A
- GTBP $11.00
- AVG Volume (30 Days)
- GNPX 24.1M
- GTBP 449.7K
- Earning Date
- GNPX 11-12-2025
- GTBP 11-13-2025
- Dividend Yield
- GNPX N/A
- GTBP N/A
- EPS Growth
- GNPX N/A
- GTBP N/A
- EPS
- GNPX N/A
- GTBP N/A
- Revenue
- GNPX N/A
- GTBP N/A
- Revenue This Year
- GNPX N/A
- GTBP N/A
- Revenue Next Year
- GNPX N/A
- GTBP N/A
- P/E Ratio
- GNPX N/A
- GTBP N/A
- Revenue Growth
- GNPX N/A
- GTBP N/A
- 52 Week Low
- GNPX $0.14
- GTBP $0.63
- 52 Week High
- GNPX $3.97
- GTBP $4.10
- Technical
- Relative Strength Index (RSI)
- GNPX 55.11
- GTBP 30.54
- Support Level
- GNPX $0.22
- GTBP $0.78
- Resistance Level
- GNPX $0.32
- GTBP $0.85
- Average True Range (ATR)
- GNPX 0.05
- GTBP 0.09
- MACD
- GNPX 0.01
- GTBP 0.03
- Stochastic Oscillator
- GNPX 39.89
- GTBP 47.22
About GNPX Genprex Inc.
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.
About GTBP GT Biopharma Inc.
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.